[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
At BIO Japan (Yokohama, Oct 7-9), Glafabra is seeking two kinds of partners: manufacturing partners (CDMOs, analytical development groups, vector partners experienced in autologous lentiviral stem-cell therapy) and Japan pharma partners interested in a licensing/co-development conversation for Glafabra's LSD programs.
This follows directly from FDA's INTERACT feedback pointing toward a defined CMC and manufacturing partnership need.
No partnership terms are being discussed publicly; any resulting relationship would be negotiated and disclosed separately.
In Yokohama this week? Reach out to arrange a meeting.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Brian Christie @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0